| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047330083 |
| P356 | DOI | 10.1016/J.NURT.2006.11.012 |
| P698 | PubMed publication ID | 17199031 |
| P5875 | ResearchGate publication ID | 6601899 |
| P2093 | author name string | Roger J Porter | |
| Chris Rundfeldt | |||
| Virinder Nohria | |||
| P2860 | cites work | A potassium channel mutation in neonatal human epilepsy | Q24320244 |
| The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits | Q28138343 | ||
| Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy | Q28292575 | ||
| Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines | Q34290637 | ||
| The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells | Q34447899 | ||
| General pharmacologic studies on the analgesic flupirtine | Q34695580 | ||
| The therapeutic potential of neuronal KCNQ channel modulators | Q35593939 | ||
| KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. | Q35682356 | ||
| Clinical aspects of epilepsy | Q36956685 | ||
| Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations | Q39544980 | ||
| Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? | Q40758069 | ||
| New visions in the pharmacology of anticonvulsion | Q41739650 | ||
| D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures | Q42638756 | ||
| Effects of retigabine on rhythmic synchronous activity of human neocortical slices | Q43590386 | ||
| Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. | Q44066396 | ||
| The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain | Q44297459 | ||
| The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation | Q44791007 | ||
| Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices | Q48290379 | ||
| Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines. | Q52371259 | ||
| Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. | Q52974740 | ||
| Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. | Q53897724 | ||
| D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. | Q53989493 | ||
| Antiepileptic drug development program: a cooperative effort of government and industry | Q69720692 | ||
| Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response | Q71526090 | ||
| Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells | Q77893179 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 149-154 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Retigabine. | |
| P478 | volume | 4 |
| Q48335756 | A pharmaco-EEG study of the interaction between ethanol and retigabine in rabbits. |
| Q30429603 | A swell in the armamentarium of antiepileptic drug targets |
| Q53193958 | Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips. |
| Q49882750 | Antiepileptic drugs in development pipeline: A recent update |
| Q36033788 | Atomic basis for therapeutic activation of neuronal potassium channels |
| Q42424886 | Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents |
| Q35717049 | Clinical utility of adjunctive retigabine in partial onset seizures in adults. |
| Q55562302 | Copper mediated C-H amination with oximes: en route to primary anilines. |
| Q41988367 | Desensitization of chemical activation by auxiliary subunits: convergence of molecular determinants critical for augmenting KCNQ1 potassium channels |
| Q37658910 | Drug interactions involving the new second- and third-generation antiepileptic drugs |
| Q34726613 | Effect of the new antiepileptic drug retigabine in a rodent model of mania |
| Q53166134 | Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy |
| Q34688725 | Emerging drugs for epilepsy |
| Q37754477 | Emerging drugs for partial onset seizures. |
| Q44669252 | Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle. |
| Q46035841 | Inhibition by an excitatory conductance: a paradox explained. |
| Q46387953 | Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. |
| Q37162392 | K+ channel modulators for the treatment of neurological disorders and autoimmune diseases |
| Q35683922 | Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. |
| Q37638688 | New and investigational antiepileptic drugs |
| Q24654230 | New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels |
| Q37950518 | Novel medications for epilepsy |
| Q42972474 | Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter |
| Q34823174 | Pharmacological management of epilepsy: recent advances and future prospects |
| Q37992162 | Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate |
| Q38059092 | Potassium channels: a review of broadening therapeutic possibilities for neurological diseases |
| Q33788071 | Potassium dynamics in the epileptic cortex: new insights on an old topic |
| Q42385228 | Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians |
| Q46667158 | Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. |
| Q36548403 | The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine |
| Q37580235 | The contribution of Kv7 channels to pregnant mouse and human myometrial contractility |
| Q37973378 | The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy |
| Q36675813 | The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential. |
| Q28245021 | Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions |
| Q37464784 | Voltage-gated potassium channels as therapeutic targets |
Search more.